The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC

J Thorac Oncol. 2022 Apr;17(4):481-486. doi: 10.1016/j.jtho.2022.01.007.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Morpholines
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles
  • Pyrimidines

Substances

  • Morpholines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • lazertinib
  • EGFR protein, human
  • ErbB Receptors